Hello Inside Pushes Metabolic Health Into Mainstream Care with BARMER Deal

Why It Matters

Integrating AI‑driven metabolic prevention into statutory health insurance gives insurers measurable outcomes while delivering personalized, gender‑responsive care that could lower long‑term chronic‑disease costs.

Key Takeaways

• Hello Inside offers free CGM program to 9M BARMER members.
• Dataset includes 66k symptom logs from 1,743 women over 90 days.
• 92% of trial participants reported reduced PMS symptoms within 60 days.
• Users open app up to 19 times daily, driving behavior change.

Pulse Analysis

Metabolic health is emerging as a cornerstone of preventive medicine, yet women have long been left out of clinical research and personalized solutions. Hello Inside, an Austrian startup, leverages continuous glucose monitoring to translate real‑time metabolic data into sex‑specific recommendations covering energy, cravings, PMS and menopause. By combining CGM streams with sleep, activity and wearable inputs, the platform creates a holistic view that goes beyond the typical data‑visualisation dashboards found in most health apps.

The company has amassed what is likely Europe’s most extensive women‑focused metabolic dataset—66,000 symptom logs from 1,743 users tracked over 90 days. Machine‑learning models, built under a “Controlled‑by‑Design” framework, rank insights against medical guidelines, ensuring auditable recommendations. Early results are promising: an IRB‑approved study showed 92 % of participants experienced a measurable drop in PMS frequency and intensity within two months, while engaged users reported weight loss and a notable rise in energy. App engagement spikes to 19 opens per day, a frequency more akin to social media than traditional health tools, fueling rapid behavior change.

Hello Inside’s pivot from a direct‑to‑consumer model to a B2B2C partnership with BARMER—Germany’s 9‑million‑member statutory insurer—marks one of the first large‑scale integrations of AI‑driven metabolic prevention into public health coverage. Offering the program at no cost to members, the insurer can now track outcomes rather than mere attendance, aligning incentives with measurable health improvements. Looking ahead, the platform plans to incorporate lactate and cortisol monitoring, expanding its biomarker suite. If insurers adopt similar outcome‑based digital therapies, the approach could reshape preventive care economics and accelerate gender‑responsive health innovation across Europe.